公开(公告)号：US20230149524A1

公开(公告)日：2023-05-18

申请号：US17753248

申请日：2020-09-02

申请人： Serum Institute of India Private Limited

发明人： Rajeev Mhalasakant Dhere ,  Sambhaji Shankar Pisal ,  Dattatreya Sarma Annamraju ,  Nikhil Dattatray Avalaskar ,  Yogesh Tukaram Hundekari ,  Anil Pirajirao Taklikar ,  Sunil Kumar Goel ,  Chandrashekhar Dwarkanath Kamat ,  Vishal Bharat Chavan

IPC分类号： A61K39/112 ,  A61K47/64 ,  A61P31/04

CPC分类号： A61K39/0275 ,  A61K47/646 ,  A61K47/6415 ,  A61P31/04 ,  A61K2039/6037

摘要： The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

公开(公告)号：US11739356B2

公开(公告)日：2023-08-29

申请号：US16611137

申请日：2018-05-03

申请人： Serum Institute of India Private Limited

发明人： Rajeev Mhalasakant Dhere ,  Sambhaji Shankar Pisal ,  Dattatreya Sarma Annamraju

IPC分类号： C12P19/04 ,  A61K39/095 ,  A61K39/00

CPC分类号： C12P19/04 ,  A61K39/095 ,  A61K2039/6037

摘要： The present invention relates to an improved process for purification of bacterial capsular polysaccharides, more specifically capsular polysaccharides of gram negative bacteria. The process comprises of concentration and dia filtration of harvest, treatment with anionic detergent and strong alkali followed by centrifugation, diafiltration and cationic detergent based precipitation of bacterial polysaccharides. The process results in significant reduction of endotoxin, protein and nucleic acid impurities thereby providing higher recovery of capsular polysaccharide with the desired O-acetyl levels. Said process is scalable, non-enzymatic, and employs fewer purification steps.